ISR asked respondents responsible for outsourcing Phase 2/3 drug development how they allocate their outsourcing budget towards CROs of various sizes and academic medical centers. As expected, large, full-service CROs receive the largest amount, accounting for 57% of outsourced spend overall. In a separate question, respondents were asked to select benefits of each provider type. Respondents selected an average of eight associated benefits for large CROs, about six for midsize and small CROs, and about four for Academic Medical Centers.

Find the the other benefits associated with each provider type, and much more in ISR’s Phase II/III Market Outlook: 2020-2024.

Originally published in Life Science Leader.

View File